Search Results

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

BIAL - R&D Investments S.A (BIAL R&D), a subsidiary of BIAL Holding, S.A., today announced the dosing of the first patient in its Phase 2 clinical trial (ACTIVATE study) to evaluate the efficacy, safety, and tolerability of BIA 28-6156.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into an agreement with BIAL in which Sunovion has granted exclusive commercial license rights in Europe for apomorphine sublingual film (APL-130277)

BIAL Biotech to be based in Cambridge, Massachusetts and will be a Research Center of Excellence dedicated to genetically-defined Parkinson’s disease

Under the terms of the agreement, BIAL will receive from Wanbang an upfront license fee of 2.5 million euros and up to 12.5 million euros in further milestones.

eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, announces positive 24-month follow-up results from its Phase I/II study evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy for retinitis pigmentosa caused by bi-allelic mutations in the PDE6b gene.

Fosun Pharma acquired China rights to market a novel treatment for Parkinson’s disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.